BiotechTube

Ciprofloxacin (Cipro, BAYQ3939) + Placebo

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bronchiectasis

Conditions

Bronchiectasis

Trial Timeline

Jun 1, 2009 → Sep 1, 2010

NCT ID
NCT00930982

About Ciprofloxacin (Cipro, BAYQ3939) + Placebo

Ciprofloxacin (Cipro, BAYQ3939) + Placebo is a phase 2 stage product being developed by Novartis for Bronchiectasis. The current trial status is completed. This product is registered under clinical trial identifier NCT00930982. Target conditions include Bronchiectasis.

What happened to similar drugs?

1 of 10 similar drugs in Bronchiectasis were approved

Approved (1) Terminated (2) Active (8)
✅Aztreonam lysineGilead SciencesApproved
❌Benralizumab + Placebo to BenralizumabAstraZenecaPhase 3
🔄Ciprofloxacin DPI (BAYQ3939) + PlaceboNovartisPhase 3
🔄Ciprofloxacin (BAYQ3939) dry powder for inhalation + Ciprofloxacin (BAYQ3939) dry powder for inhalation + Placebo + PlaceboNovartisPhase 3
🔄AZLI + PlaceboGilead SciencesPhase 3
🔄AZLI + PlaceboGilead SciencesPhase 3
🔄HSK31858, tablet + PlaceboHaisco Pharmaceutical GroupPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00930982Phase 2Completed

Competing Products

20 competing products in Bronchiectasis

See all competitors
ProductCompanyStageHype Score
Benralizumab + Placebo to BenralizumabAstraZenecaPhase 3
32
AZD9668 + PlaceboAstraZenecaPhase 2
35
AZD5069 + PlaceboAstraZenecaPhase 2
35
AZD0292AstraZenecaPhase 2
42
TIP + TIP and placebo + PlaceboNovartisPhase 2
35
Ciprofloxacin DPI (BAYQ3939) + PlaceboNovartisPhase 3
40
Placebo to Ciprofloxacin DPI (BAYQ3939)NovartisPre-clinical
26
Ciprofloxacin (BAYQ3939) dry powder for inhalation + Ciprofloxacin (BAYQ3939) dry powder for inhalation + Placebo + PlaceboNovartisPhase 3
40
QBW251 + PlaceboNovartisPhase 2
27
AZLI + PlaceboGilead SciencesPhase 3
40
Aztreonam lysineGilead SciencesApproved
35
AZLIGilead SciencesPhase 2
35
AZLI + PlaceboGilead SciencesPhase 3
40
Itepekimab (SAR440340) + PlaceboSanofiPhase 2
35
CSL787 + PlaceboCSLPhase 1
29
CSL787 + PlaceboCSLPhase 2
42
HSK31858, tablet + PlaceboHaisco Pharmaceutical GroupPhase 3
47
HSK31858 + placeboHaisco Pharmaceutical GroupPhase 2
35
Group A + Group BBayerPre-clinical
23
BAY85-8501 + PlaceboBayerPhase 2
32